1 Result: Pulmonx
Pulmonx Beats Estimates; Strategic Move Boosts TransCode Therapeutics
October 30th, 2023
Pulmonx Corporation (Nasdaq: LUNG) reported a narrower loss than expected in the third quarter of 2023, posting a loss of $(0.39) per share, surpassing the consensus estimate loss of $(0.43) per share. The company's quarterly sales stood at $17.67 mi. Read more
Want To Find Some News?
News By Industries
Recent Post
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login